Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP

• Status: Completed
• Trial end date: 2009-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, extension, Phase III study to evaluate the long-term safety and efficacy of MRA in patients with RA who participated in Study MRA220JP or MRA221JP.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chugai Pharmaceutical

Criteria

Inclusion criteria

• RA patients who participated in the previous studies

• Patients who completed the last observation in the previous studies

• Patients who were confirmed to have no problems with safety in the previous studies.

Exclusion criteria

• Patients with Class IV Steinbrocker functional disorder at evaluation within 4 weeks before treatment with the investigational product

• Patients who were not enrolled by 3 months after the last observation day of the previous study